The FTC has filed a lawsuit against major pharmacy benefit managers (PBMs), accusing them of inflating insulin prices through anticompetitive practices that harm patients. This legal battle could lead to significant PBM reforms, ensuring fair pricing for essential medications like insulin. The lawsuit highlights the rising cost of insulin, forcing many patients to ration their medication or go without due to high out-of-pocket expenses. If successful, the case could set a new precedent in holding PBMs accountable and improving access to affordable medications for millions of patients.